SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today that QSYMIA® (phentermine and topiramate extended-release capsules ...

Surescripts®, the nation’s leading health intelligence network, introduces its Patient Experience product, Script Corner™, to ...

Like other successful and innovative companies, GoodRx has adapted and evolved to stay relevant, viable, and true to its mission. Improving healthcare and patient outcomes requires that stakeholders ...

On Thursday, GoodRx (GDRX) launched a new way to pay for and get prescriptions filled that mimics the e-commerce experience. The company will eventually build it out for all its pharmacy partners. The ...

Sanofi's Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site's growing business with large pharma ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Today, GoodRx (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., was named to the fourth-annual TIME100 Most Influential Companies ...

Screen: GoodRx allows patients to find deals on prescription drugs. Has GoodRx Holdings Inc. finally regained its mojo? Two years ago, the Santa Monica-based prescription drug discounter was in a ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...